ROS1 and non-small cell lung carcinoma: Gene mutation or fusion of activating epidermal growth factor receptor (EGFR), ERBB1, anaplastic lymphoma kinase (ALK), ROS1 protooncogene receptor tyrosine kinase (ROS1), and serine/threonine protein kinase b-Raf (BRAF) is the most common target in the treatment of NSCLC kinase inhibitors [3], and more and more new driving mutations have been found.